In addition, this enhanced GR signaling could induce a robust expression of oncoproteins associated with therapy-resistance, including LEDGF/p75 and CLU, leading to poor response to conventional treatments in AA PCa patients. The gene discussed is PSIP1; the disease is posterior cortical atrophy.